Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 40

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 40
---
 otherwise determined appropriate, as determined by the Compensation Committee.

| ​                    | ​ |          ​ | ​ |          ​ |
| ​                    |   | 2024 Bonus |   | 2025 Bonus |
| ​                    | ​ |     Target | ​ |     Target |
| Name                 | ​ |         -% | ​ |         -% |
| Gene Mack(1)         |   |         35 |   |         50 |
| Gianluca Fuggetta(2) | ​ |          — | ​ |         30 |
| Matthias Alder(3)    |   |         50 |   |          — |
| Evan Ballantyne(4)   |   |          — |   |          — |

| (1) | Mr. Mack served as our Chief Financial Officer from April 8, 2024 to January 7, 2025. From June 25, 2024 to January 7, 2025, Mr. Mack also served as our Interim Chief Executive Officer, a role for which he received no additional compensation. He was appointed as our permanent Chief Executive Officer effective January 6, 2025. The Compensation Committee determined, at its own discretion, that Mr. Mack had earned 30% of his target bonus for 2024 based on additional achievements and his overall performance, equal to a bonus of $150,000. |

| (2) | Mr. Fuggetta served as our Principal Financial Officer from February 21, 2024 to April 5, 2024. He was appointed as our Senior Vice President Finance and Principal Financial Officer effective January 6, 2025. The Compensation Committee determined, at its own discretion, that Mr. Fuggetta had earned a 10% discretionary bonus, equal to a bonus of ₣18,000. |

| (3) | Mr. Alder was appointed as our Chief Executive Officer effective September 20, 2022 and served as our Chief Executive Officer until June 25, 2024. |

| (4) | Mr. Ballantyne was appointed as our Chief Financial Officer effective April 10, 2023 and served as our Chief Financial Officer until March 1, 2024. |

In December 2024, the Compensation Committee completed an evaluation of our overall performance for 2024 and the named executive officers’ respective contributions in achieving this performance. The Compensation Committee’s review was based on company